Mithra Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
Mithra Pharmaceuticals's earnings have been declining at an average annual rate of -23.7%, while the Pharmaceuticals industry saw earnings growing at 10.4% annually. Revenues have been declining at an average rate of 12% per year.
Key information
-23.7%
Earnings growth rate
-13.4%
EPS growth rate
| Pharmaceuticals Industry Growth | 12.4% |
| Revenue growth rate | -12.0% |
| Return on equity | n/a |
| Net Margin | -432.1% |
| Next Earnings Update | 30 Apr 2024 |
Recent past performance updates
Recent updates
Not Many Are Piling Into Mithra Pharmaceuticals SA (EBR:MITRA) Stock Yet As It Plummets 26%
Apr 06
Revenues Working Against Mithra Pharmaceuticals SA's (EBR:MITRA) Share Price Following 39% Dive
Feb 07Party Time: Brokers Just Made Major Increases To Their Mithra Pharmaceuticals SA (EBR:MITRA) Earnings Forecasts
Nov 09These Analysts Just Made A Huge Downgrade To Their Mithra Pharmaceuticals SA (EBR:MITRA) EPS Forecasts
Oct 05Take Care Before Diving Into The Deep End On Mithra Pharmaceuticals SA (EBR:MITRA)
May 23Bullish: Analysts Just Made A Huge Upgrade To Their Mithra Pharmaceuticals SA (EBR:MITRA) Forecasts
Aug 11Growth Investors: Industry Analysts Just Upgraded Their Mithra Pharmaceuticals SA (EBR:MITRA) Revenue Forecasts By 21%
Mar 13Mithra Pharmaceuticals (EBR:MITRA) Is Making Moderate Use Of Debt
Dec 22Some Mithra Pharmaceuticals SA (EBR:MITRA) Analysts Just Made A Major Cut To Next Year's Estimates
Nov 24Here's Why Mithra Pharmaceuticals (EBR:MITRA) Can Afford Some Debt
Jun 07When Will Mithra Pharmaceuticals SA (EBR:MITRA) Turn A Profit?
May 10Is Mithra Pharmaceuticals SA's (EBR:MITRA) Shareholder Ownership Skewed Towards Insiders?
Mar 18We're Not So Sure You Should Rely on Mithra Pharmaceuticals' (EBR:MITRA) Statutory Earnings
Feb 16Analysts Expect Breakeven For Mithra Pharmaceuticals SA (EBR:MITRA) Before Long
Jan 21
Some Mithra Pharmaceuticals SA (EBR:MITRA) Analysts Just Made A Major Cut To Next Year's Estimates
Nov 29Revenue & Expenses BreakdownBeta
How Mithra Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 40 | -174 | 24 | 63 |
| 30 Sep 23 | 51 | -126 | 21 | 66 |
| 30 Jun 23 | 63 | -79 | 17 | 69 |
| 31 Mar 23 | 65 | -69 | 17 | 66 |
| 31 Dec 22 | 67 | -60 | 17 | 64 |
| 30 Sep 22 | 44 | -76 | 16 | 70 |
| 30 Jun 22 | 22 | -93 | 16 | 76 |
| 31 Mar 22 | 22 | -105 | 15 | 81 |
| 31 Dec 21 | 23 | -117 | 14 | 85 |
| 30 Sep 21 | 21 | -115 | 15 | 86 |
| 30 Jun 21 | 19 | -113 | 16 | 87 |
| 31 Mar 21 | 14 | -103 | 17 | 83 |
| 31 Dec 20 | 9 | -92 | 17 | 78 |
| 30 Sep 20 | 44 | -31 | 17 | 71 |
| 30 Jun 20 | 79 | 29 | 16 | 64 |
| 31 Mar 20 | 88 | 1 | 16 | 61 |
| 31 Dec 19 | 97 | -27 | 16 | 57 |
| 30 Sep 19 | 84 | -54 | 15 | 47 |
| 30 Jun 19 | 71 | -82 | 14 | 37 |
| 31 Mar 19 | 64 | -55 | 12 | 36 |
| 31 Dec 18 | 58 | -28 | 11 | 36 |
| 30 Sep 18 | 46 | -41 | 10 | 39 |
| 30 Jun 18 | 33 | -53 | 10 | 42 |
| 31 Mar 18 | 33 | -46 | 10 | 45 |
| 31 Dec 17 | 32 | -38 | 10 | 48 |
| 30 Sep 17 | 26 | -37 | 12 | 46 |
| 30 Jun 17 | 20 | -36 | 13 | 43 |
| 31 Mar 17 | 21 | -36 | 14 | 39 |
| 31 Dec 16 | 22 | -35 | 16 | 34 |
| 30 Sep 16 | 21 | -29 | 17 | 29 |
| 30 Jun 16 | 20 | -23 | 19 | 24 |
| 31 Mar 16 | 20 | -16 | 17 | 17 |
| 31 Dec 15 | 20 | -10 | 15 | 9 |
| 30 Sep 15 | 19 | -9 | 13 | 7 |
| 30 Jun 15 | 18 | -8 | 10 | 4 |
| 31 Mar 15 | 19 | -5 | 10 | 3 |
| 31 Dec 14 | 19 | -3 | 10 | 3 |
| 31 Dec 13 | 18 | -2 | 8 | 1 |
Quality Earnings: MITRA is currently unprofitable.
Growing Profit Margin: MITRA is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: MITRA is unprofitable, and losses have increased over the past 5 years at a rate of 23.7% per year.
Accelerating Growth: Unable to compare MITRA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MITRA is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (3.8%).
Return on Equity
High ROE: MITRA's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.